The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibodys latest Press releases

To the archive

2020-06-15

Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis

Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced positive top-line data from its 52-week trial investigating the...[read more]

2020-06-15

Affibody Announces Termination of ABY-039 (FcRn) Program...[read more]

2020-05-25

Notice to attend Annual General Meeting...[read more]